ZANGRILLI, ARIANNA
 Distribuzione geografica
Continente #
NA - Nord America 5.376
EU - Europa 442
AS - Asia 151
OC - Oceania 4
SA - Sud America 3
AF - Africa 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.979
Nazione #
US - Stati Uniti d'America 5.371
CN - Cina 95
IE - Irlanda 88
DE - Germania 68
SE - Svezia 67
IT - Italia 58
UA - Ucraina 52
FR - Francia 36
GB - Regno Unito 33
RU - Federazione Russa 18
KR - Corea 17
UZ - Uzbekistan 13
FI - Finlandia 10
KG - Kirghizistan 7
IN - India 6
AU - Australia 4
CA - Canada 4
BE - Belgio 3
HK - Hong Kong 3
RO - Romania 3
SG - Singapore 3
BR - Brasile 2
CH - Svizzera 2
EG - Egitto 2
NL - Olanda 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
BG - Bulgaria 1
EU - Europa 1
IQ - Iraq 1
IR - Iran 1
JP - Giappone 1
KH - Cambogia 1
MD - Moldavia 1
MX - Messico 1
MY - Malesia 1
TR - Turchia 1
Totale 5.979
Città #
Wilmington 1.600
Houston 1.294
Woodbridge 1.156
Fairfield 240
Chandler 209
Ashburn 125
Ann Arbor 110
Seattle 97
Cambridge 91
Dublin 83
Medford 64
Dearborn 46
Jacksonville 43
Lawrence 30
Beijing 28
New York 25
San Diego 18
Zhengzhou 18
Rome 12
Hefei 8
Seoul 8
Menlo Park 7
Norwalk 7
Redmond 7
Redwood City 7
Shanghai 7
Esslingen am Neckar 5
Jinan 4
Kilburn 4
Nanjing 4
Palo Alto 4
Sedico 4
Sydney 4
Augusta 3
Brussels 3
Detroit 3
Genazzano 3
London 3
Mülheim 3
Nanchang 3
Paris 3
Aprilia 2
Atlanta 2
Bari 2
Boardman 2
Bologna 2
Cairo 2
Central 2
Falls Church 2
Fuzhou 2
Giugliano In Campania 2
Guidonia 2
Hebei 2
Joliet 2
Kunming 2
Milan 2
Nürnberg 2
Pune 2
Saint Petersburg 2
San Francisco 2
Shenyang 2
Stockertown 2
Stockport 2
Suceava 2
Sundern 2
Toronto 2
Wuhan 2
Acton 1
Albano Laziale 1
Ankara 1
Ardabil 1
Auburn Hills 1
Bellingham 1
Boston 1
Büdelsdorf 1
Chengdu 1
Chicago 1
Chisinau 1
Clearwater 1
Dubai 1
Grezzago 1
Groningen 1
Guadalajara 1
Guangzhou 1
Hangzhou 1
Helsinki 1
Hounslow 1
Kuala Lumpur 1
Las Vegas 1
Latina 1
Leawood 1
Mountain View 1
Mussidan 1
Nashville 1
Nijmegen 1
Pantin 1
Phnom Penh 1
Pisa 1
Portland 1
Quzhou 1
Totale 5.478
Nome #
Efficacy and Safety of Subcutaneous Anti-Tumor Necrosis Factor-Alpha Agents, Etanercept and Adalimumab, in Elderly Patients Affected by Psoriasis and Psoriatic Arthritis: An Observational Long-Term Study 397
Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study. 388
Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics 374
Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis 374
HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study. 370
Quality of life of psoriatic patients evaluated by a new psychometric assessment tool: PsoDisk 351
Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey 346
TNF-α antagonists and nail psoriasis: An open, 24-week, prospective cohort study in adult patients with psoriasis 340
Erysipeloid cutaneous metastasis from bladder carcinoma 333
Long-term treatment of psoriatic patients with adalimumab reduces disease severity and maintains a favorable lipid pattern and a low Atherogenic Index. 309
Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey 282
Radiologically significant joint improvement in a patient affected by psoriatic arthritis treated with adalimumab 274
Efficacy and safety of adalimumab after failure of other anti-TNFα agents for plaque-type psoriasis: clinician behavior in real life clinical practice 219
Paradoxical case effects of psoriasis following adalimumab therapy: A case series 215
Adalimumab in severe plaque psoriasis of childhood: A multi-center, retrospective real-life study up to 52 weeks observation 201
One drug and two diseases: A case of multidrug-resistant hidradenitis suppurativa and psoriasis treated with apremilast 201
Adalimumab in children and adolescents with severe plaque psoriasis: a safety evaluation 146
Real life experience of apremilast in psoriasis and arthritis psoriatic patients: preliminary results on metabolic biomarkers 144
Efficacy and safety of Adalimumab in difficult-to-treat psoriasis 141
Detection of adalimumab and anti-adalimumab levels by ELISA: clinical considerations 110
Ixekizumab: One drug for an enigmatic psoriasis 84
Psoriasis in difficult to treat areas: treatment role in improving health-related quality of life and perception of the disease stigma 82
Omalizumab and adalimumab: a winning couple 82
A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic 79
A linear forehead lesion caused by intralesional injection of triamcinolone acetonide and treated with hyaluronic acid filler: case report 70
Risankizumab: How to choose the right dose in clinical practice? 55
Adalimumab for moderate to severe psoriasis: an open-label, retrospective 3-year study 55
Paradoxical psoriasis induced by anti-TNFα treatment: evaluation of disease-specific clinical and genetic markers 51
Long-term efficacy of adalimumab in generalized pustular psoriasis 47
Clinical severity instruments 39
Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: A 52-week Italian real-life experience 4
Totale 6.163
Categoria #
all - tutte 13.970
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.970


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019294 0 0 0 0 0 0 0 0 0 0 145 149
2019/20201.664 105 113 95 139 156 188 169 143 127 188 113 128
2020/20211.433 108 124 116 155 223 200 183 169 45 46 37 27
2021/2022340 17 31 21 26 10 20 18 13 19 51 20 94
2022/2023474 37 53 24 56 41 101 38 27 51 13 18 15
2023/2024121 16 3 8 5 19 29 12 23 4 2 0 0
Totale 6.163